The objective of the present study is aimed to formulate and evaluate sustained-release Mebeverine hydrochloride capsules using the Pelletization technique. Mebeverine hydrochloride, an anti-spasmodic drug is highly water soluble with a half-life of 2h and is suitable to develop sustained action for the treatment of irritable bowel syndrome. Mebeverine hydrochloride prolongs medication release in the GIT and, as a result, into the plasma, while reducing the frequency of drug administration, adverse effects, and patient compliance. Mebeverine hydrochloride were prepared by using polymers The drug-polymer and excipient compatibility was defined by the FTIR studies in the pre-formulation study. The calibration curve for the drug is plotted and checked the physicochemical properties. Six formulations (F1-F6) of Mebeverine hydrochloride pellets were prepared using different quantities of Ethylcellulose N 50 and other standard excipients. In vitro, drug release studies were performed for the pellets for 1.2, 4, 6, 8, and 12hrs. The optimized formulation F6 showed 76.8 % drug release after 12h showing that ethyl cellulose N 50 acts as a rate-controlling agent. The drug release of the chosen formulation follows first-order kinetics with a zero-order mechanism, according to absorption kinetics.